 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...1920212223242526272829...3738» |
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Real-World Evidence: Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center. (Pubmed Central) - Mar 31, 2020
TNBC, > 2 organs involved and being younger than 70 years old were independent prognosis factors for worse OS. Remarkably, less incidence of grade 4-toxicity compared to previous studies was found.
- || Halaven (eribulin mesylate) / Eisai, cyclophosphamide intravenous / Generic mfg., docetaxel / Generic mfg.
Clinical, P2 data, Journal: A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. (Pubmed Central) - Mar 29, 2020
No unexpected toxicities were observed. Our results also provided no suggestion that ErC is a neoadjuvant treatment with greater efficacy than that of standard regimens.
- | paclitaxel / Generic mfg.
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. (Pubmed Central) - Mar 28, 2020
However, AZD8186 has enhanced efficacy when combined with paclitaxel and anti-PD1 in vivo. Further study is needed to determine optimal combination therapies for PTEN-deficient solid tumors.
- || doxorubicin hydrochloride / Generic mfg.
Clinical, Review, Journal: First-Line Therapy for Metastatic Soft Tissue Sarcoma. (Pubmed Central) - Mar 26, 2020
Molecular characterization of sarcoma subtypes will likely improve understanding of these very diverse tumors and improve target characterization. The ongoing efforts in better understanding these rare tumors hold the key to make a difference in the outcome of these patients.
- ||||||||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Trial suspension, Metastases: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Mar 25, 2020
P3, N=400, Suspended, Sponsor: Immunomedics, Inc.
The ongoing efforts in better understanding these rare tumors hold the key to make a difference in the outcome of these patients. Recruiting --> Suspended
- || Halaven (eribulin mesylate) / Eisai
Clinical, Clinical data, Journal: The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study. (Pubmed Central) - Mar 24, 2020
In conclusion, there was a significant difference in PFS between patients with L-sarcoma and non-L-sarcoma following treatment with eribulin. The anti-tumor potential of eribulin was evident in patients with UPS.
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Mar 24, 2020
P2, N=32, Active, not recruiting, Sponsor: Virginia G. Kaklamani
The anti-tumor potential of eribulin was evident in patients with UPS. Trial primary completion date: Dec 2019 --> Dec 2020
- || Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, Clinical, Journal: Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. (Pubmed Central) - Mar 20, 2020
P4
Despite the early study closure, preoperative E following AT showed clinical and biological activity in triple negative breast cancer patients. Furthermore, the modulation of β-catenin pathway core proteins, supposedly outside the domain of epithelial-mesenchymal transition, claims for further investigation.
- Bavencio (avelumab) / EMD Serono, Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients (clinicaltrials.gov) - Mar 16, 2020
P1b, N=6, Terminated, Sponsor: Monika Joshi, MD
Furthermore, the modulation of β-catenin pathway core proteins, supposedly outside the domain of epithelial-mesenchymal transition, claims for further investigation. N=24 --> 6 | Trial completion date: Jul 2021 --> Oct 2019 | Recruiting --> Terminated | Trial primary completion date: Jun 2020 --> Oct 2019; Funder Decision
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Mar 11, 2020
P2, N=46, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Journal: Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. (Pubmed Central) - Mar 10, 2020
The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.
- | Halaven (eribulin mesylate) / Eisai
Trial termination: Study of Eribulin in Children With Cancer to Determine Safety (clinicaltrials.gov) - Mar 10, 2020
P1, N=3, Terminated, Sponsor: University of Oklahoma
The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer. Completed --> Terminated; Competing study opened
- || Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Combination therapy: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) - Mar 10, 2020
P1/2, N=44, Completed, Sponsor: University of California, San Francisco
Completed --> Terminated; Competing study opened Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Dec 2019
- doxorubicin hydrochloride / Generic mfg.
Validation of a Cardio-Oncology Risk-Management Algorithm for a New Cardio-Oncology Service and Evaluation of Cardiotoxicity Trends in Breast Cancer Patients () - Mar 9, 2020 - Abstract #HOPA2020HOPA_399;
This is a retrospective chart review of adult, female breast cancer patients who initiated a new chemotherapy regimen containing at least one of the following cardiotoxic chemotherapy agents: doxorubicin, epirubicin, trastuzumab, pertuzumab, ado-trastuzumab emtansine, eribulin, lapatinib, ribociclib, fluorouracil, and capecitabine between January 1, 2017 and December 31, 2017. Pending
- vinorelbine tartrate / Generic mfg.
[VIRTUAL] HEALTH UTILITY IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC TNBC () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_628;
METHODS : This study examined the EQ-5D-3L data collected from patients enrolled in the KEYNOTE-119 trial, a multicenter, worldwide, randomized Phase III trial comparing pembrolizumab to chemotherapy per physician’s choice (Capecitabine, vinorelbine, gemcitabine or eribulin) for subjects receiving second or third treatment for mTNBC...The deterioration of utility associated with disease progression and time to death is clinically meaningful. The utility values estimated from the study will inform economic evaluations of treatments in metastatic TNBC.
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Mar 2, 2020
P2, N=78, Suspended, Sponsor: National Cancer Institute (NCI)
The utility values estimated from the study will inform economic evaluations of treatments in metastatic TNBC. Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
- || Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Biomarker, Clinical, P2 data, Journal, Tumor Mutational Burden, PARP Biomarker: Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). (Pubmed Central) - Feb 28, 2020
P2
Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021 Mutation signature 3, found in about 30% of MBCs regardless of hormone receptor status, was associated with short PFS for patients with cytotoxic chemotherapy.
- || Halaven (eribulin mesylate) / Eisai
Clinical, P2 data, Journal, Combination therapy: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer. (Pubmed Central) - Feb 28, 2020
Mutation signature 3, found in about 30% of MBCs regardless of hormone receptor status, was associated with short PFS for patients with cytotoxic chemotherapy. The combination of eribulin and S-1 is safe and effective for treatment in patients with ABC and poor prognosis.
- ||| dacarbazine / Generic mfg., Halaven (eribulin mesylate) / Eisai
Clinical, P3 data, Journal: Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. (Pubmed Central) - Feb 26, 2020
Efficacy of eribulin in patients with leiomyosarcoma was comparable to that of dacarbazine. Both agents had manageable safety profiles.
- || Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Clinical, P2 data, Journal, HEOR: Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11). (Pubmed Central) - Feb 26, 2020
In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC.
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Feb 25, 2020
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC. Trial completion date: Dec 2019 --> Dec 2020
- || Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. (Pubmed Central) - Feb 24, 2020
Neither grade 4 peripheral neuropathy nor febrile neutropenia occurred. Conclusions ETP therapy showed acceptable efficacy and safety and is a potential first-line therapy for patients with HER2-positive MBC.
- | Halaven (eribulin mesylate) / Eisai
Journal: Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling. (Pubmed Central) - Feb 24, 2020
CLP reduced the viability of MDA-MB-231 and MDA-MB-468 TNBC cell lines but not human breast healthy epithelial cell line (MCF-12A) similar to eribulin, standard...This study concludes that CLP suppresses growth and migration by attenuating cell cycle of TNBC cell lines via EGFR and CD151 signaling. Thus, exploring the EGFR and CD151 signaling pathway targeted by CLP may provide a new approach in the treatment of TNBC.
- || vinorelbine tartrate / Generic mfg.
Preclinical, Review, Journal: Assessing the utility of in vitro microtubule assays for studying mechanisms of peripheral neuropathy with the microtubule inhibitor class of cancer chemotherapy. (Pubmed Central) - Feb 23, 2020
These are possible mechanisms for causing less severe deleterious effects on MTs in peripheral nerves leading to reduced severity of CIPN. Our analyses demonstrated that in vitro tools used to study the mechanisms of action in inducing severe CIPN (i.e MTI interactions with MTs) warrant further investigation and may be useful for developing next generation MTIs with reduced CIPN.
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Real-World Evidence: Utilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER). (Pubmed Central) - Feb 23, 2020
Our analyses demonstrated that in vitro tools used to study the mechanisms of action in inducing severe CIPN (i.e MTI interactions with MTs) warrant further investigation and may be useful for developing next generation MTIs with reduced CIPN. No abstract available
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: A nationwide, multi-institutional retrospective study of efficacy and safety of eribulin in Korean breast cancer patients (REMARK). (Pubmed Central) - Feb 23, 2020
No abstract available No abstract available
- |||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial primary completion date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Feb 11, 2020
P3, N=529, Active, not recruiting, Sponsor: Immunomedics, Inc.
No abstract available Trial primary completion date: Dec 2019 --> Apr 2020
- || Halaven (eribulin mesylate) / Eisai
Clinical, Observational data, Journal, Real-World Evidence: Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. (Pubmed Central) - Feb 8, 2020
P=N/A
Trial primary completion date: Dec 2019 --> Apr 2020 Eribulin was generally well tolerated and showed antitumor activity against STSs, including rare subtypes that currently have few treatment options.
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Circulating Tumor Cells: Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer. (Pubmed Central) - Feb 7, 2020
Patients who received eribulin as the first chemotherapy for metastatic disease showed longer OS (p = 0.006). Our data suggest that determining numbers of both mesenchymal and epithelial CTCs might predict survival for patients receiving eribulin.
- eribulin/farletuzumab ADC (MORAB-202) / Eisai
A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors (Amphitheatre Bordeaux) - Feb 7, 2020 - Abstract #TAT2020TAT_91;
P1
Expansion part in the dose range of 0.9 and 1.2 mg/kg is underway for ovarian cancer (including primary peritoneal carcinoma and fallopian tube carcinoma). Legal entity responsible for the study: Eisai Co.
- | Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Surgery: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 7, 2020
P1, N=24, Recruiting, Sponsor: Presage Biosciences
Legal entity responsible for the study: Eisai Co. Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Trial primary completion date, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - Feb 6, 2020
P=N/A, N=35, Recruiting, Sponsor: University of Wisconsin, Madison
Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Trial primary completion date: Jun 2020 --> Jun 2021
- | Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 5, 2020
P1, N=247, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal: Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. (Pubmed Central) - Jan 31, 2020
Our results mirror those of the published randomized trials. The effect of anti-HER2 therapies addition in this setting still needs to be defined.
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Clinical, Journal: Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report. (Pubmed Central) - Jan 30, 2020
The effect of anti-HER2 therapies addition in this setting still needs to be defined. Trabectedin should be considered as a treatment option for DDLPS even in cases of numerous failed prior chemotherapy regimens.
- | Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg.
Journal: Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein. (Pubmed Central) - Jan 30, 2020
Eribulin also increased MDR1 promoter activity in human breast cancer MCF7 cells. The results suggest that the microtubule-targeting anticancer drug eribulin can induce the drug efflux transporter P-glycoprotein via PXR in human intestinal and breast cancer cells and thus influence the efficacy of anticancer drugs.
- || vinorelbine tartrate / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical, Journal, BRCA Biomarker, PARP Biomarker: OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (Pubmed Central) - Jan 29, 2020
P3
While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease. Olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure.
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date: EMEG-E-01: Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin (clinicaltrials.gov) - Jan 27, 2020
P=N/A, N=95, Completed, Sponsor: Centre Georges Francois Leclerc
Olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure. Recruiting --> Completed | Trial completion date: Sep 2021 --> Jan 2020
- vinorelbine tartrate / Generic mfg.
MYCN pathway activation in combination with p53 dysregulation in fallopian tube secretory epithelial cells drives ovarian/fallopian tube carcinosarcoma (Trade Area Level 2&3) - Jan 24, 2020 - Abstract #LCC2020LCC_201;
While most tumours respond well initially, many relapse. To achieve complete and sustained responses in HGSOC and OCS we are currently investigating combination treatments in our PDX models, including the combination of anti-microtubule agents or PARP inhibitor, depending on the genotype of the tumour, with immunotherapy (pembrolizumab) in human immune system (HIS) mice.
- | fluorouracil / Generic mfg.
Journal, Tumor Mutational Burden: The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. (Pubmed Central) - Jan 24, 2020
Clinically relevant subgroups of tumors are identified, exhibiting either homologous recombination deficiency (13%), high tumor mutational burden (11%) or specific alterations (24%) linked to sensitivity to FDA-approved drugs. This study provides insights into the biology of metastatic breast cancer and identifies clinically useful genomic features for the future improvement of patient management.
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Jan 21, 2020
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
This study provides insights into the biology of metastatic breast cancer and identifies clinically useful genomic features for the future improvement of patient management. Trial primary completion date: Dec 2019 --> Dec 2020
- Halaven (eribulin mesylate) / Eisai
Neutrophil to lymphocyte ratio (NLR) may predict survival and efficacy of eribulin in advanced breast cancer patients (Poster Area/Exhibition Hall) - Jan 19, 2020 - Abstract #EBCC2020EBCC_407;
Trial primary completion date: Dec 2019 --> Dec 2020 Abstract will be shown 2 weeks before the conference (with consent of the author)
- Halaven (eribulin mesylate) / Eisai
Treatment with eribulin could suppress epithelial-mesenchymal transition (EMT) characteristics in tumors of patients with metastatic breast cancer (Poster Area/Exhibition Hall) - Jan 19, 2020 - Abstract #EBCC2020EBCC_404;
Abstract will be shown 2 weeks before the conference (with consent of the author) Abstract will be shown 2 weeks before the conference (with consent of the author)
- Halaven (eribulin mesylate) / Eisai
An exploratory phase II study of Eribulin re-challenge after short term therapy of 5-fuluorouracil for HER2-negative, advanced or recurrent breast cancer (Poster Area/Exhibition Hall) - Jan 19, 2020 - Abstract #EBCC2020EBCC_400;
Abstract will be shown 2 weeks before the conference (with consent of the author) Abstract will be shown 2 weeks before the conference (with consent of the author)
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: real life experience. (Poster Area/Exhibition Hall) - Jan 19, 2020 - Abstract #EBCC2020EBCC_380;
Abstract will be shown 2 weeks before the conference (with consent of the author) Abstract will be shown 2 weeks before the conference (with consent of the author)
- | Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Adverse events: Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment: Two Case Reports. (Pubmed Central) - Jan 15, 2020
These two cases suggest that spontaneous pneumothorax may occur as an adverse event of eribulin treatment in such patients. We should therefore be alert for the potential development of pneumothorax during eribulin treatment of patients with STS and lung metastases.
- |||| Onzeald (etirinotecan pegol) / Nektar Therap
Enrollment closed, Metastases: ATTAIN: A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (clinicaltrials.gov) - Jan 15, 2020
P3, N=178, Active, not recruiting, Sponsor: Nektar Therapeutics
We should therefore be alert for the potential development of pneumothorax during eribulin treatment of patients with STS and lung metastases. Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jan 14, 2020
P2, N=37, Recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Jan 8, 2020
P1, N=19, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021 Trial completion date: Dec 2019 --> Apr 2020
- || Halaven (eribulin mesylate) / Eisai
Clinical, Observational data, Journal: Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. (Pubmed Central) - Jan 8, 2020
In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8). Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.